MACROGENICS INC (MGNX) Stock Overview
USA - NASDAQ:MGNX - US5560991094 - Common Stock
MGNX Key Statistics, Chart & Performance
The current stock price of MGNX is 1.6 USD. In the past month the price decreased by -6.73%. In the past year, price decreased by -58.79%.
MGNX Latest News, Press Relases and Analysis
MGNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.93B | ||
| ARGX | ARGENX SE - ADR | 89.07 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.96 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 9.34 | 21.93B |
Related stock screener links
About MGNX
Company Profile
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 341 full-time employees. The company went IPO on 2013-10-10. The firm generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. The company is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Company Info
MACROGENICS INC
9704 Medical Center Drive
Rockville MARYLAND 20850 US
CEO: Scott Koenig
Employees: 341
Phone: 13012515172
MACROGENICS INC / MGNX FAQ
Can you describe the business of MACROGENICS INC?
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 341 full-time employees. The company went IPO on 2013-10-10. The firm generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. The company is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
What is the current price of MGNX stock?
The current stock price of MGNX is 1.6 USD. The price decreased by -5.33% in the last trading session.
Does MGNX stock pay dividends?
MGNX does not pay a dividend.
What is the ChartMill rating of MACROGENICS INC stock?
MGNX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does MACROGENICS INC have?
MACROGENICS INC (MGNX) currently has 341 employees.
When does MACROGENICS INC (MGNX) report earnings?
MACROGENICS INC (MGNX) will report earnings on 2025-11-11.
MGNX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to MGNX. When comparing the yearly performance of all stocks, MGNX is a bad performer in the overall market: 91.97% of all stocks are doing better.
MGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MGNX. MGNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MGNX Financial Highlights
Over the last trailing twelve months MGNX reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS increased by 74.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.83% | ||
| ROE | -78.08% | ||
| Debt/Equity | 0 |
MGNX Forecast & Estimates
13 analysts have analysed MGNX and the average price target is 3.47 USD. This implies a price increase of 116.75% is expected in the next year compared to the current price of 1.6.
For the next year, analysts expect an EPS growth of -88.32% and a revenue growth -57.15% for MGNX